Affimed to Present at Upcoming Investor Conferences

Rhea-AI Summary

Heidelberg, Germany, November 4, 2020 – Affimed N.V. (Nasdaq: AFMD) announces management participation in key investor conferences this November. The Jefferies Virtual London Healthcare Conference is scheduled for November 17-19, with a presentation on November 17 at 12:20 p.m. GMT. Additionally, Affimed will host meetings during the SVB Leerink Oncology 1x1 Day on November 19. A live webcast of the Jefferies presentation will be available on Affimed's website, followed by a 30-day replay. For more information, contact Affimed's investor relations.

Heidelberg, Germany, November 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the company’s management will participate in the following investor conferences during the month of November:

Jefferies Virtual London Healthcare Conference (November 17-19, 2020)
Presentation date: Tuesday, November 17, 2020
Presentation time: 12:20 p.m. GMT (7:20 a.m. EST)

SVB Leerink Oncology 1x1 Day (November 19, 2020)
Affimed will host meetings with investors at the conference

A live webcast of the Jefferies Healthcare Conference presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

For more information on the conferences or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

Affimed Investor Contact
Alexander Fudukidis

Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

 

FAQ

What are the dates for Affimed's upcoming investor conferences in November 2020?

Affimed will participate in the Jefferies Virtual London Healthcare Conference from November 17-19, 2020, and the SVB Leerink Oncology 1x1 Day on November 19, 2020.

When will Affimed present at the Jefferies Virtual London Healthcare Conference?

Affimed's presentation at the Jefferies Virtual London Healthcare Conference is scheduled for November 17, 2020, at 12:20 p.m. GMT.

Where can I watch the webcast of Affimed's presentation?

A live webcast of Affimed's presentation at the Jefferies Healthcare Conference can be accessed on Affimed’s website.

What is the focus of Affimed's clinical-stage development?

Affimed is focused on immuno-oncology, developing therapies to treat hematologic and solid tumors.

What studies are currently enrolling patients at Affimed?

Affimed is enrolling patients in a study for AFM13 targeting CD30-positive relapsed/refractory peripheral T cell lymphoma and a Phase 1/2a study for AFM24 targeting advanced EGFR-expressing solid tumors.